As we reflect on the past year, the EHC is deeply grateful for the dedication of our NMOs, partners, and community. Let’s move forward with renewed energy!

The EHC welcomed the opportunity to contribute to the European Commission’s public consultation on the draft implementing regulation on Joint Scientific Consultations (JSC) for Medicinal Products, for which we issued nine recommendations.

We are delighted to introduce you to our latest EHC addition, Stéphanie Maya Bravo, who joined us in October 2024 as Administration Officer.

The European Haemophilia Consortium (EHC) held its annual General Assembly (GA) during the EHC Conference 2024 in Sofia, Bulgaria, from 4 to 6 October.

On 10 September 2024, the EHC hosted its first post-pandemic Round Table on “Current Issues in von Willebrand Disease” in Brussels, Belgium.

Mid-June 2024, the EHC, NBDF and WFH were made aware of a manufacturing deviation in the production lines of several products for the treatment of haemophilia and other coagulopathies manufactured by Novo Nordisk in Denmark.